A University of Pennsylvania School of Engineering and Applied Science team led by Neil K.R. Sehgal, Sharath Chandra Guntuku, Lyle Ungar, and Jena Shaw Tronieri published in Nature Health (Vol. 1, Issue 8, page 806; DOI 10.1038/s44360-026-00108-y) an AI-driven analysis of 410,198 Reddit posts from 67,008 users self-reporting use of semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) between May 2019 and June 2025. Gastrointestinal side effects dominated as expected (nausea 36.9%, fatigue 16.7%, vomiting 16.3%, constipation 15.3%, diarrhea 12.6%), and 43.5% of users reported at least one side effect. Two categories emerged as underreported in trials and worth investigation: reproductive symptoms including menstrual cycle changes and heavy bleeding (~4%), and thermoregulation symptoms (chills, hot flashes). The authors caution that Reddit users skew younger, male, and U.S.-based and note the analysis cannot establish causation. The hypothalamus regulates hunger, hormones, reproduction, and body temperature — a plausible biological substrate. Coverage syndicated Saturday September 12, 2026 (ScienceDaily and other outlets) after the Sept 13 journal publication date.
A 2026 scoping review in the Journal of Cachexia, Sarcopenia and Muscle catalogs peptides studied as therapeutic candidates and biomarkers in skeletal muscle wasting — covering sarcopenia, cancer cachexia, and ICU-related atrophy. The review documents MIF1/MIF2 myostatin peptide inhibitors, cachexia-targeting platform peptides, and the broader role of GH-axis peptides (CJC-1295, ipamorelin, tesamorelin) in muscle homeostasis. The clinical urgency lands harder now than it did pre-2024: Nature Reviews Endocrinology recently flagged sarcopenia and frailty as under-recognized GLP-1 receptor agonist side effects, with up to 40% of GLP-1-induced weight loss attributable to lean mass in the highest-loss patients. The review surfaces non-GLP-1 peptide candidates that could be paired with incretin therapy to protect muscle.
Bloomgarden's commentary in the Journal of Diabetes (2026, vol 18, e70204) frames the clinical case for moving past first-generation GLP-1 agonists, focusing on two limits: gastrointestinal intolerance that forces dose reduction or discontinuation in 15-30% of patients depending on agent and titration, and a non-responder problem where roughly 10-20% of treated individuals fail to reach the expected weight-loss range. With 12% of US adults reported to have at least temporarily received a GLP-1 agonist, the population-level stakes are large. The commentary lands alongside the Frontiers Drug Discovery 'Beyond GLP-1' review as one of two academic pieces this month formalizing the post-incretin research agenda — and aligns with the AstraZeneca ASCEND triple-mechanism thesis, the petrelintide + enicepatide combination program, and Lilly's quintuple agonist disclosed for ADA 2026.